AstraZeneca Gross Profit 2010-2024 | AZN

AstraZeneca annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • AstraZeneca gross profit for the quarter ending March 31, 2024 was $10.461B, a 16.57% increase year-over-year.
  • AstraZeneca gross profit for the twelve months ending March 31, 2024 was $39.030B, a 18.08% increase year-over-year.
  • AstraZeneca annual gross profit for 2023 was $37.543B, a 17.47% increase from 2022.
  • AstraZeneca annual gross profit for 2022 was $31.96B, a 27.94% increase from 2021.
  • AstraZeneca annual gross profit for 2021 was $24.98B, a 17.18% increase from 2020.
AstraZeneca Annual Gross Profit
(Millions of US $)
2023 $37,543
2022 $31,960
2021 $24,980
2020 $21,318
2019 $19,463
2018 $17,154
2017 $18,147
2016 $18,876
2015 $20,062
2014 $20,705
2013 $20,545
2012 $22,580
2011 $27,565
2010 $26,880
2009 $27,029
AstraZeneca Quarterly Gross Profit
(Millions of US $)
2024-03-31 $10,461
2023-12-31 $9,716
2023-09-30 $9,397
2023-06-30 $9,456
2023-03-31 $8,974
2022-12-31 $8,308
2022-09-30 $8,000
2022-06-30 $7,773
2022-03-31 $7,879
2021-12-31 $7,386
2021-09-30 $6,109
2021-06-30 $6,029
2021-03-31 $5,456
2020-12-31 $5,885
2020-09-30 $5,208
2020-06-30 $5,291
2020-03-31 $4,934
2019-12-31 $5,286
2019-09-30 $5,055
2019-06-30 $4,760
2019-03-31 $4,362
2018-12-31 $4,780
2018-09-30 $4,187
2018-06-30 $4,143
2018-03-31 $4,044
2017-12-31 $4,552
2017-09-30 $4,983
2017-06-30 $4,101
2017-03-31 $4,511
2016-12-31 $4,425
2016-09-30 $4,799
2016-06-30 $4,541
2016-03-31 $5,111
2015-12-31 $5,130
2015-09-30 $4,904
2015-06-30 $5,240
2015-03-31 $4,788
2014-12-31 $5,049
2014-09-30 $5,194
2014-06-30 $5,455
2014-03-31 $5,007
2013-12-31 $5,499
2013-09-30 $5,012
2013-06-30 $4,915
2013-03-31 $5,119
2012-12-31 $5,884
2012-09-30 $5,408
2012-06-30 $5,314
2012-03-31 $5,974
2011-12-31 $7,044
2011-09-30 $6,620
2011-06-30 $6,948
2011-03-31 $6,953
2010-12-31 $6,858
2010-09-30 $6,374
2010-06-30 $6,726
2010-03-31 $6,922
2009-12-31 $7,280
2009-09-30 $6,937
2009-06-30 $6,494
2009-03-31 $6,318
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $243.139B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11